Transcatheter Aortic Valve Replacement

Juan Crestanello, MD
Interim Director, Division of Cardiac Surgery
Associate Professor
Division of Cardiac Surgery
The Ohio State University Wexner Medical Center

Aortic Stenosis

Symptomatic **Asymptomatic**



Leon ME et al. NEJM 2010, Otto CM et al. Circulation 1997

Transcatheter AVR

Patients with Severe AS Treated with Surgery



- Advanced age
- Left ventricular dysfunction
- Multiple comorbidities
- Frailty
- Increased "surgical risk"

Transcatheter AVR

Edwards Sapien

FDA approved

Medtronic CoreValve

Inoperable FDA approved
High risk: in trials

Edwards Sapien TAVR



Transcatheter AVR



CoreValve Deployment Self Expandable



The Trials



PARTNER TRIAL



PARTNER TRIAL



Inoperable Aortic Stenosis
TAVR vs. Medical Management



Inoperable Aortic Stenosis
TAVR vs. Medical Management



TAVR: 80% on NYHA class I or II

Inoperable Aortic Stenosis
TAVR vs. Medical Management



Permission to use Partner Trial information and images provided courtesy of Edwards Lifesciences.

Inoperable Aortic Stenosis
TAVR vs. Medical Management



Inoperable Aortic Stenosis
TAVR vs. Medical Management

- **Medical management did not change the natural history of aortic stenosis**
- **TAVR relieved aortic stenosis**
- **TAVR was superior to medical therapy:**
  - **Decreased all cause mortality**
  - **Decreased cardiovascular mortality**
  - **Decreased rate of rehospitalization**
  - **Improved NYHA functional class**

PARTNER TRIAL



Permission to use Partner Trial information and images provided courtesy of Edwards Lifesciences.

High Risk Aortic Stenosis
TAVR vs. AVR



High Risk Aortic Stenosis
TAVR vs. AVR



80% on NYHA class I or II

High Risk Aortic Stenosis
TAVR vs. AVR



TAVR increased risk of early stroke

High Risk Aortic Stenosis
TAVR vs. AVR



High Risk Aortic Stenosis
Paravalvular Aortic Regurgitation



Paravalvular Aortic Regurgitation



High Risk Aortic Stenosis
Paravalvular Aortic Regurgitation



Permission to use Partner Trial information and images provided courtesy of Edwards Lifesciences.

High Risk Aortic Stenosis
TAVR vs. SAVR

- **TAVR and SAVR effectively relieved AS**
- **Mortality was similar up to 2 years**
- **NYHA class was similar**
- **30 day stroke rate was higher in TAVR**
- **TAVR was associated with PVL**
- **Mild moderate and severe PVL resulted in increased mortality**


CoreValve US Clinical Trials
CoreValve Trial
Pivotal Trial Design
CoreValve US Pivotal Trials
Extreme Risk
High Risk
Iliofemoral Access > 18 Fr Sheath
Randomization 1:1
Yes
No
Versus
CoreValve Iliofemoral
CoreValve Non-Iliofemoral
CoreValve
SAVR
N=487
N=147
Jeffrey J. Popma, MD. CoreValve US Pivotal Trial Extreme Risk Iliofemoral Study Results. Data presented at TCT. San Francisco, California. October 2013.


CoreValve US Clinical Trials
Aortic Stenosis Extreme Risk
Primary Endpoint
All Cause Mortality or Major Stroke
All Cause Mortality or Major Stroke
P < 0.0001
Performance Goal = 43%
9.3%
[6.7,12.0]
25.5%
[21.6,29.4]
Months Post-Procedure
Jeffrey J. Popma, MD. CoreValve US Pivotal Trial Extreme Risk Iliofemoral Study Results. Data presented at TCT. San Francisco, California. October 2013.


CoreValve US Clinical Trials
Aortic Stenosis Extreme Risk
1 Year Mortality
All Cause Mortality
Cardiovascular Mortality
All Cause Mortality (%)
24.0%
7.9%
7.9%
17.9%
Months Post-Procedure
Jeffrey J. Popma, MD. CoreValve US Pivotal Trial Extreme Risk Iliofemoral Study Results. Data presented at TCT. San Francisco, California. October 2013.


CoreValve US Clinical Trials
Aortic Stenosis Extreme Risk
Major Stroke
Major Stroke
Major Stroke (%)
2.4%
4.1%
Months Post-Procedure
Jeffrey J. Popma, MD. CoreValve US Pivotal Trial Extreme Risk Iliofemoral Study Results. Data presented at TCT. San Francisco, California. October 2013.

Aortic Stenosis Extreme Risk

CoreValve US Clinical Trials

Secondary Endpoints

Events*	1 Month	1 Year
Any Stroke, %	3.9	6.7
Major, %	2.4	4.1
Minor, %	1.7	3.1
Myocardial Infarction, %	1.3	2.0
Reintervention, %	1.3	2.0
VARC Bleeding, %	35.1	41.4
Life Threatening or Disabling, %	11.7	16.6
Major, %	24.1	27.6
Major Vascular Complications, %	8.3	8.5
Permanent Pacemaker Implant, %	22.2	27.1
Per ACC Guidelines, %	17.4	19.9

* Percentages obtained from Kaplan Meier estimates

Jeffrey J. Popma, MD. CoreValve US Pivotal Trial Extreme Risk Iliofemoral Study Results. Data presented at TCT. San Francisco, California. October 2013.

Aortic Stenosis Extreme Risk

CoreValve US Clinical Trials

NYHA Class Survivors

90% of Patients Improved at Least 1 NYHA Class by 1 Year

60% of Patients Improved at Least 2 NYHA Classes by 1 Year



Jeffrey J. Popma, MD. CoreValve US Pivotal Trial Extreme Risk Iliofemoral Study Results. Data presented at TCT. San Francisco, California. October 2013.

Aortic Stenosis Extreme Risk

CoreValve US Clinical Trials

Echocardiographic Findings



Jeffrey J. Popma, MD. CoreValve US Pivotal Trial Extreme Risk Iliofemoral Study Results. Data presented at TCT. San Francisco, California. October 2013.

Aortic Stenosis Extreme Risk

CoreValve US Clinical Trials

Perivalvular Aortic Regurgitation

Paravalvular Regurgitation



Jeffrey J. Popma, MD. CoreValve US Pivotal Trial Extreme Risk Iliofemoral Study Results. Data presented at TCT. San Francisco, California. October 2013.





CoreValve Extreme Risk

- **TAVR relieved aortic stenosis**
- **TAVR reduced mortality and stroke rate at one year**
- **Low rate of stroke**
- **Mild and moderate PVL was not associated with increased mortality**



Valve in Valve



Ongoing and Upcoming Trials

Intermediate Risk	High Risk	Extreme Risk
SURTAVI Trial	CoreValve Pivotal Trial	CoreValve Pivotal Trial
	Expanded Use	Expanded Use
PARTNER II	PARTNER A	PARTNER B

The Structural Heart Disease Team

TAVR with Medtronic CoreValve: Femoral Approach

Barry George, MD
Director
Advanced Catheter-Based Therapeutics and Structural Heart Disease
Associate Professor – Clinical
Department of Cardiovascular Medicine
The Ohio State University Wexner Medical Center

CoreValve Delivery Options



CoreValve Delivery Options



Transfemoral Step by Step



Transfemoral Step by Step



Vascular Access

Vascular Access

- Femoral artery cut down (percutaneous) for delivery sheath
- Contralateral femoral artery placement of 6F sheath.

Vascular Access

- Femoral artery cut down (percutaneous) for delivery sheath

Vascular Access

- Femoral artery cut down (percutaneous) for delivery sheath

5-0 Prolene purse string Needle and guidewire

Administer Heparin to achieve ACT>300 s

Vascular Access

- Femoral artery cut down (percutaneous) for delivery sheath

6 French Sheath placement

Pigtail placement into descending thoracic aorta

Vascular Access

- Femoral artery cut down (percutaneous) for delivery sheath

Insertion Amplatz Super Stiff guidewire over pigtail catheter

Vascular Access

- Femoral artery cut down (percutaneous) for delivery sheath



Arterial dilatation with 12,14 and 18 F dilators over Amplatz Super Stiff guidewire

Vascular Access

- Femoral artery cut down (percutaneous) for delivery sheath



Placement of 18 F sheath

Vascular Access

- Contralateral femoral artery placement of 6F sheath.

Percutaneous arterial access

6F Sheath and pigtail

Implant projection



Determination of implantation projection

- Alignment of all 3 cusps of aortic valve in a single plane.





Pigtail advance to non-coronary sinus

Crossing Aortic Valve

Initial Hemodynamic Assessment

Crossing the Aortic Valve

- AL 2 catheter with straight guidewire
- AP projection





Crossing the Aortic Valve

- Exchange guidewire
- ROA projection
- Pigtail placement in LV apex



Initial Hemodynamic Assessment

- LV and Aortic pressure





Placement of stiff guidewire in the LV apex

- RAO projection
- Amplatz Super Stiff ST1 (pigtail configuration)



Aortic Valvuloplasty

Aortic balloon valvuloplasty

- Balloons:
  - Z MED (NuMED Inc)
  - NuCLEUS Ballon (NuMED Inc)
  - True Balloon (Loma Vista Medical)
- Balloon size: smaller diameter of aortic annulus
- Pacing rate: 160-180 bpm
- Screw-in temporary pacing lead
- If patient has a PPM,transvenous pacer in the OR.
- No valvuloplasty in:
  - Low EF patients <30-35%
  - Large plaque-calcifications in the aorta or sinus of Valsalva
  - Valve in valve

Aortic balloon valvuloplasty

- Pacer on
- Balloon up
- Ballon down
- Pacer off





CoreValve Implantation

CoreValve Implantation

- **CoreValve is loaded into the delivery system before the valvuloplasty**



CoreValve in the delivery capsule



Optimal implantation depth 2 to 6 mm

Depth of implantation



Correct	**Too deep**	**Too shallow**	**Irregular**	**Large**
No AI	AI AV block	AI Pop out	annulus AI	annulus AI

CoreValve insertion and advancement into the aortic root



CoreValve insertion and advancement into the aortic root



CoreValve Deployment

CoreValve Deployment

- Position adjustments
  - Operator #1: Pulling or pushing delivery catheter
  - Operator #2: Pulling or pushing guidewire



Pushing guidewire: CoreValve moves out (toward the aorta)





Pulling guidewire: CoreValve moves in (toward ventricle)

CoreValve Deployment

- Node 0



CoreValve Deployment

- Node 1



CoreValve Deployment

- Node 2 to 3/4



- Rapid ventricular pacing

CoreValve Deployment

- Final release



Nosecone

- Recapture of the nosecone in the descending aorta and removal of the delivery catheter

Valve Function Assessment

Valve Function Assessment

- Angiography



Valve Function Assessment

- Hemodynamics



Aortic Systolic Pressure

Aortic Diastolic Pressure

Left Ventricular End-diastolic Pressure

Valve Function Assessment

- Hemodynamics



Aortic Regurgitation Index

$$\frac{\text{Ao Diastolic - LVEDP}}{\text{Ao Systolic}} > 0.25$$

Aortic Diastolic Pressure >40 mmHg

Valve Function Assessment

- Hemodynamics



Aortic Regurgitation Index

$$\frac{\text{Ao Diastolic - LVEDP}}{\text{Ao Systolic}} > 0.25$$

$$\frac{(62-22)}{135} = 0.29$$

Valve Function Assessment

- Echocardiography



Sheath Removal Access Repair

Sheath removal

- Over stiff guidewire
- Inject contrast through sheath
- Contralateral pigtail in the aortic bifurcation



Sheath removal

- If iliac artery rupture:
  - Advance sheath and dilator over stiff guidewire
  - Place Coda aortic occlusion balloon through contralateral pigtail (arterial sheath may need to be exchange)
  - Place coverstent through ipsilateral sheath

Arteriotomy repair